



Universiteit  
Leiden  
The Netherlands

## **5-ASA - colorectal cancer - cell death : an intriguing threesome**

Koelink, P.J.

### **Citation**

Koelink, P. J. (2010, January 14). *5-ASA - colorectal cancer - cell death : an intriguing threesome*. Retrieved from <https://hdl.handle.net/1887/14563>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14563>


**Note:** To cite this publication please use the final published version (if applicable).

# **Chapter 1**

General introduction and outline of this thesis

## General introduction

Cancer of the large bowel, colorectal cancer (CRC), is the second cause of cancer-related death in the Western world, resulting in nearly 500,000 deaths each year worldwide <sup>1</sup>. In spite of better diagnostic possibilities most patients with CRC are beyond reasonable prospect of cure by the time therapy, if any, is instituted; 40-50% of the patients probably will die within 5 year (SEER Cancer Statistics Review USA, NCIN data briefing UK). The most important prognostic factor for patients suffering from CRC is the spread of the tumour at the time of diagnosis, as indicated by the Dukes' staging (*Figure 1*) <sup>2</sup>. Patients with a tumour that has not invaded the submucosa (Dukes' A) have a >90 % 5-year survival rate. Patients with a tumor that has invaded the muscularis propria, but has not spread to adjacent lymph nodes (Dukes' B) have a 70-80 % 5-year survival rate. When tumour cells have spread to adjacent lymph nodes (Dukes' C) or even metastasized to distant organs, (Dukes' D), 5-year survival rates drop to <50% and <10% respectively (SEER Cancer Statistics Review USA, NCIN data briefing UK).



*Figure 1: Dukes' staging of the progression of CRC with 5-year survival rates indicated below.*


The main primary treatment of CRC is removing the bowel segment in which the tumour is located. Despite efforts to improve surgery this is still not ideal, about 50 % of the patients develop recurrence after removal of the primary tumour. Patients are treated with radio- and chemotherapy, before and/or after resection of the primary tumour, but clinical/survival effects are limited <sup>3</sup>. Therefore, the prevention of CRC has become increasingly important, especially in people at higher risk.

## Genetic and environmental factors

CRC most commonly occur sporadically, only a small percentage (~5%) occurs in the setting of well-defined inherited syndromes, like familial adenomatous polyposis (FAP) and hereditary-non-polyposis-colorectal cancer (HNPCC) or Lynch syndrome<sup>4-6</sup>. Both syndromes have an autosomal mode of inheritance with the development of CRC at a younger age. FAP individuals develop 100s-1000s adenomatous polyps in their intestine that ultimately progress to carcinoma. CRC is further determined by environmental exposures, i.e., physical inactivity, alcohol consumption, smoking and dietary components<sup>7</sup>. The high fat, low fiber Western type diet is believed to cause the increased incidence of CRC in the Western world<sup>8,9</sup>.

## CRC development

Colorectal carcinomas are thought to arise from a precancerous lesion, the benign adenoma (polyp). Progression from a benign adenoma to a malignant carcinoma passes through a series of well-defined histological stages, accompanied by genetic alterations, known as the adenoma-carcinoma sequence (*Figure 2*)<sup>10,11</sup>.




*Figure 2: The adenoma-carcinoma sequence introduced by Fearon and Vogelstein<sup>10</sup>*

Two different mechanisms of genomic instability give rise to CRC development, microsatellite instability and chromosomal instability. Chromosomal instability is mainly a consequence of genetic alterations that involve the activation of oncogenes (*K-Ras*) or the inactivation of tumor suppressors (*APC*, *p53*) and is mainly found in sporadic CRC. The inactivation of the adenomatous polyposis coli (*APC*) tumour suppressor gene is found as the initiating mutation in most sporadic colorectal cancers<sup>12</sup>. Patients with FAP have a germ-line mutation in this gene<sup>13,14</sup>.

Mutations in the DNA mismatch repair (MMR)-system result in a failure to repair errors that occur during DNA replication, resulting in an accumulation of frame-shift mutations in small repetitive non-coding sequences, called microsatellites<sup>15, 16</sup>. This microsatellite instability (MIS) is the hallmark of CRC in HNPCC patients, mainly resulting from mutations in one of the MMR genes: *MLH1*, *PMS2*, *MSH2* and *MSH6*, and is more frequently found in tumours of the proximal (right-sided) colon<sup>17</sup>.

### Wnt signaling

The canonical Wnt pathway is important in regulating multiple aspects of intestinal tissue homeostasis<sup>18</sup>. Upon activation of Frizzled receptors on the cell surface the  $\beta$ -catenin degradation complex, consisting of axins, APC and glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), is disrupted resulting in stabilization and nuclear accumulation of  $\beta$ -catenin. In the nucleus  $\beta$ -catenin binds to the T-cell factor-4 (TCF-4) transcription factor resulting in the transcriptional activation of Wnt/TCF4 target genes, including cyclinD1 and c-MYC (*Figure 3*)<sup>19</sup>.




*Figure 3: The canonical Wnt signalling pathway.*

The majority of CRC is initiated by activating mutations in this pathway and either remove the tumour suppressors APC or axin or activate the proto-oncogene  $\beta$ -catenin, resulting in constant activation of the pathway<sup>20</sup>.

## Transforming Growth Factor- $\beta$ signalling

The Transforming Growth Factor (TGF)- $\beta$  superfamily of proteins consists of TGF- $\beta$ s, Bone Morphogenetic Proteins (BMPs) and actividins, which play an important role in intercellular communication, cell proliferation, cell motility, functional differentiation and apoptosis<sup>21, 22</sup>.

TGF- $\beta$  binds to a heteromeric complex of transmembrane kinase receptors, TGF- $\beta$ R-I and TGF- $\beta$ R-II. Upon TGF- $\beta$  binding to TGF- $\beta$ R-II, TGF- $\beta$ R-I is recruited to the receptor




*Figure 4: The TGF- $\beta$  signalling pathway.*

complex and transphosphorylated by TGF- $\beta$ R-II. TGF- $\beta$ R-I, activin-receptor-like-kinase-5 (ALK-5), in turn phosphorylates the Smad regulatory proteins, Smad2 and Smad3, which associate with the co-Smad, Smad4, and translocate to the nucleus, interacting with other transcription factors, in a cell specific manner, to regulate a panel of TGF- $\beta$ -responsive genes (Figure 5)<sup>23</sup>. Some of the downstream genes are important cell-cycle checkpoint genes, including the cyclin dependent kinase inhibitors p21 and p27<sup>24, 25</sup>, which activation leads to a growth arrest. Therefore, TGF- $\beta$  prevents progression through the cell cycle and induces apoptosis, acting as a tumour suppressor, in normal intestinal epithelium. Other downstream

targets, like plasminogen activator inhibitor-1 (PAI-1) and metalloproteinases (MMPs), contribute to the progression of cancer<sup>26, 27</sup>, reflecting the dual role of TGF- $\beta$  in cancer. Several mutations in the TGF- $\beta$  signalling pathway, like in Smad4 and TGF- $\beta$ R-II, contribute to CRC carcinogenesis, leaving most CRC resistant to TGF- $\beta$  induced growth inhibition<sup>28-30</sup>. Because CRC usually show a high expression of TGF- $\beta$ <sup>31-33</sup> it can act as a tumour promoter during the late stages of colorectal carcinogenesis, via promotion of tumour angiogenesis, increased production of extracellular matrix (ECM) and proteolytic enzymes, increased motility and immunosuppression<sup>34</sup>. TGF- $\beta$  also drives differentiation of fibroblasts into myofibroblasts, which are abundantly present in colorectal carcinomas<sup>35, 36</sup>, important in the interaction with carcinoma cells in cancer progression and metastasis<sup>37</sup>.

## Regulated cell death


Programmed cell death, i.e., apoptosis, is an important mechanism to maintain tissue homeostasis as a counter balance of cell proliferation, especially in tissues with a high cell



turnover like the intestine, in which the complete epithelial layer is renewed every 4-5 days. In normal intestinal crypts apoptosis is initiated at the top of the crypts, and cell proliferation is stimulated in the bottom of the crypt, by high intracellular Wnt signalling (Figure 5)<sup>19,38</sup>.

*Figure 5: Normal intestinal crypt homeostasis.*

The process by which a normal cell transforms into a tumour cell can be by becoming apoptosis resistant<sup>39</sup>. Apoptosis is accompanied by several distinct morphological features, like chromosomal condensation, cytoplasmic shrinkage, and blebbing of the cell membrane (phosphatidylserine externalization)<sup>40</sup>, and biochemical features, like the activation of cys-dependent asp proteases, the caspases<sup>41</sup>. Neoplastic cells are usually less sensitive to apoptotic signals, due to deregulation of the two main apoptotic pathways, the extrinsic and intrinsic pathway<sup>42,43</sup>. Activation of surface FAS receptors triggers the extrinsic pathway, activating caspase-3 via activation of caspase-8 (Figure 6)<sup>44,45</sup>. In the intrinsic (or mitochondrial) pathway, intracellular stress (genomic stress, defects in DNA repair, replication and cell division) is detected by p53, and causes mitochondrial membrane potentiation, via pro-apoptotic proteins in the mitochondrial membrane (Bcl-2), resulting in the mitochondrial release/outflux of cytochrome-c. Cytochrome-c interacts, together with Apaf-1, in the cytosol activating caspase-9 and eventually caspase-3<sup>46</sup>. So, both pathways activate the effector caspase-3, which is responsible for cleaving most cellular substrates during the apoptotic process<sup>47</sup>.



*Figure 6: Intrinsic and extrinsic apoptotic pathways.*

### The prognostic value of apoptosis in CRC

The adenoma-carcinoma sequence is generally accompanied by a resistance to apoptosis<sup>48,49</sup>. Most studies show a relation between apoptosis and proliferation<sup>50-53</sup>, which is heavily increased in neoplastic lesions, and therefore the apoptotic level of neoplastic lesions is also higher compared with normal. To evaluate whether tumour cell apoptosis levels have clinical relevance for the patients' outcome several studies have been done<sup>50,54</sup>. Apoptosis can be determined by counting the number of apoptotic tumour cells, either identified by morphological changes on haematoxylin and eosin (H&E) stained slides, but also by immunohistochemical stainings for DNA fragmentation [TdT-mediated dUTP-biotin nick end-labeling (TUNEL)] or caspase-3 degraded cytokeratin 18 (M30). These detection methods have different specificities, TUNEL is not specific for apoptotic epithelial cells, other apoptotic cells and even some necrotic cells with DNA fragmentation are also stained, while M30 immunohistochemistry specifically detects only apoptotic epithelial cells<sup>55,56</sup>. The prognostic relevance of the apoptotic index, as determined with these techniques, is not completely clear; some studies have found that low levels of apoptosis are associated with a



worse clinical outcome (disease recurrence or death), while others have found the opposite or no association<sup>50</sup>. Determination of total cellular apoptosis, by caspase-3 activity assay on CRC protein homogenates has shown significant clinical value for the patient in most studies<sup>57-60</sup>, which might indicate the importance of non-epithelial apoptosis in the tumour, as further discussed in **chapter 2**.

### **Non-apoptotic cell death in tumourigenesis and colorectal cancer**

Mitotic catastrophe is a form of cell death that results from an abnormal cell division. Non-proper chromosome segregation and cell division leads to the formation of large non-viable cells with multiple micronuclei which are the feature of mitotic catastrophe<sup>61</sup>. The observation that tumour cells are frequently deficient in cell-cycle checkpoints implies that they are particularly susceptible to the induction of mitotic catastrophe. It is indeed one of the main forms of cell death induced by radiation and chemotherapy in tumour cells<sup>62,63</sup>. The induction of mitotic catastrophe can play a role in tumour regression, as tumours that display a mitotic catastrophe response correspond to enhanced tumour regression after therapy<sup>64</sup>. The clinical value of mitotic catastrophe in general in CRC is unclear as research has been limited due to lack of specific markers.

### **Colitis-associated CRC**

People suffering from the two main forms of chronic inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's Disease (CD) are at increased risk of developing CRC<sup>65,66</sup>. As CRC is responsible for up to 15% of all deaths in patients with IBD it is one of the most feared complications of IBD<sup>67</sup>. Several factors are known to increase the risk of CRC, including age of onset, duration and severity of colitis<sup>68,69</sup>. In contrast to sporadic CRC, the precancerous lesions in IBD-associated CRC can be polypoid, flat or diffuse. Detection of the dysplastic lesions by programmed colonoscopy screening, followed by surgical resection, is the current approach for prevention of IBD-associated CRC<sup>70-72</sup>.

### **CRC chemoprevention**

Non-steroidal-anti-inflammatory-drugs (NSAIDs) are compounds used in the treatment of inflammatory conditions, like rheumatoid arthritis (RA) and IBD. The use of several of these NSAIDs, like sulindac and aspirin, has been found to reduce the CRC risk in large epidemiological, controlled patient, and animal studies<sup>73-83</sup>. Therefore, these NSAIDs have drawn attention as agents that might prevent the development of CRC, i.e.,

chemopreventive agents<sup>79</sup>. Unfortunately, most of these NSAIDs have severe side-effects, like intestinal ulcers, bleeding, perforation and renal toxicity<sup>84-86</sup>, and are therefore not useful for a long-term treatment in a chemopreventive strategy to CRC. Moreover, the exact mechanisms by which these NSAIDs reduce CRC risk are unknown<sup>80, 87, 88</sup>. One of the main mechanisms is the inhibition of cyclooxygenase (COX) enzymes<sup>89, 90</sup>. These enzymes are involved in the synthesis of prostaglandin, a molecule involved in pain signalling and maintaining the gastrointestinal lining. COX-1 is present in most tissues as a housekeeper gene and maintains normal gastric mucosa and influences kidney function. COX-2 is inducible by inflammatory mediators, including cytokines, and is upregulated in colorectal adenomas and carcinomas<sup>91-97</sup>. The inhibition of COX-2 reduces inflammatory damage and contributes to the anti-inflammatory effects of NSAIDs, and is also believed to underlie the chemopreventive effect. However, the simultaneous inhibition of COX-1 is related to most of the side-effects of NSAID's<sup>86, 98</sup>. In the 1990s some very promising selective COX-2 inhibitors were developed, like celecoxib<sup>99-101</sup>, which were unfortunately found to increase heart failure and strokes<sup>102</sup>. Because some NSAIDs have therapeutic effects besides COX inhibition<sup>80, 87, 103, 104</sup>, their therapeutic targets remain to be elucidated and can be of value for the development of new treatment strategies.

### **Sulphasalazine and 5-aminosalicylic acid**

Sulphasalazine has been used for the induction and maintenance of remission in IBD patients for decades<sup>105</sup>. Sulphasalazine is a conjugate of 5-aminosalicylic acid (5-ASA) and sulphapyridine (SP). In the late 1970s 5-ASA was found to be the active moiety in sulphasalazine<sup>106, 107</sup>, and this was the starting point of the clinical use of monocomponent 5-ASA or mesalazine therapy. The mode of action of 5-ASA, however, is not completely understood<sup>108</sup>. The effect of 5-ASA is related to the intraluminal concentration of the drug<sup>109</sup>. It is transformed to the inactive acetylated 5-ASA by the intestinal cells and bacteria present<sup>110, 111</sup>. Most epidemiological studies strongly support a chemopreventive effect of long-term use of 5-ASA in the development of CRC in UC patients, although some studies have failed to show a preventive effect, shown in *Table 1*<sup>69, 112-122</sup>.

Table 1: Studies investigating effects of 5-ASA on CRC development in IBD patients.

<i>Author, year</i>	<i>Study</i>	<i>Patients</i>	<i>Cases</i>	<i>Outcome</i>	<i>Medication</i>	<i>OR (95 % CI)</i>
Pinczowski, 1994	Case control	UC	102	Cancer	Sulphasalazine	<b>0.38 (0.20-0.69)</b>
Moody, 1996	Cohort	UC	10	Cancer	Sulphasalazine	<b>0.08 (0.02-0.29)</b>
Lashner, 1997	Cohort	UC	29	Both	Sulphasalazine / 5-ASA	0.95 (0.34-2.70)
Eaden, 2001	Case control	UC	102	Cancer	Sulphasalazine / 5-ASA	0.47 (0.22-1.00)
Lindberg, 2001	Cohort	UC	50	Cancer Dysplasia	Sulphasalazine	0.28 (0.06-1.42) 0.73 (0.25-2.10)
Bernstein, 2003	Case control	CD/UC	14/11	Cancer	5-ASA	1.22 (0.32-4.62)
Rubin, 2003 <sup>&amp;</sup>	Case control	UC	26	Cancer	5-ASA	<b>0.28 (0.09-0.85)</b>
Rutter, 2004	Case control	UC	68	Cancer	5-ASA	2.06 (0.61-6.94)
Van Staa, 2005	Case control	IBD CD UC	9 15 76	Cancer	Sulphasalazine / 5-ASA	<b>0.54 (0.35-0.86)</b>
Velayos, 2005 <sup>#</sup>	Meta-analysis	IBD	-	Cancer Dysplasia Both	5-ASA	<b>0.51 (0.37-0.69)</b> 1.18 (0.41-3.43) <b>0.51 (0.38-0.69)</b>
Velayos, 2006	Case control	UC	188	Cancer	5-ASA	<b>0.4 (0.2-0.9)</b>
Terdiman, 2007	Case control	IBD	364	Cancer	5-ASA	0.97 (0.77-1.23)

<sup>&</sup> Abstract publication. <sup>#</sup> Velayos et al. 2005 used all the 9 studies reported before. Statistically different odds ratios (OR) of 5-ASA treated IBD patients are shown in bold.

5-ASA is an attractive agent in a chemopreventive (and treatment) strategy with respect to CRC, as long standing experience with 5-ASA containing medication has learned that the drug is well tolerated without severe side-effects and gastrointestinal toxicity. The mechanisms behind the chemopreventative effect of 5-ASA are not completely understood, but were first thought to be related to the anti-inflammatory effects of 5-ASA, reducing damage to the colonic mucosa and thereby reducing the CRC risk. More recently, direct anti-cancer effects of 5-ASA have been described, including inhibitory effects on the Wnt pathway<sup>123-137</sup>.

## Aim and outline of the thesis

The main aim of the studies described in this thesis was to evaluate the effect of 5-ASA on the development of CRC. This thesis, therefore, focuses on the direct anti-cancer effects of 5-ASA on CRC cells *in vitro* and *in vivo*, particularly the induction of apoptosis. In addition, the effect of 5-ASA on the development of both sporadic and IBD-associated CRC was evaluated in a novel mouse model. Also the clinical impact of apoptosis in CRC patients was investigated.

The clinical impact of apoptosis in intestinal tissue on the behaviour of CRC, as described in **Chapter 2**, shows that low levels of CRC apoptosis is an important risk factor in these patients. The products of cell death go into the circulation and the levels measured in plasma of CRC patients are correlated to tumour progression and clinical outcome, as reported in **Chapter 3**. The effects of 5-ASA on CRC cell proliferation and cell death *in vitro* are described in **Chapter 4**. The study on the apoptosis inducing effect of 5-ASA on colorectal tumour cells in human patients *in vivo* is described in **Chapter 5**. The *in vitro* studies described in **Chapter 6** relate to the regulatory effect of 5-ASA on the TGF- $\beta$  pathway in CRC cells and colonic fibroblasts. A novel mouse model to study CRC was developed and also used in combination with an intestinal inflammation model, in order to evaluate the effect of 5-ASA treatment on the development of both sporadic and IBD-associated CRC, as described in **Chapter 7**. **Chapter 8** describes another aspect of 5-ASA, that is its modulatory effect on radiotherapy of CRC cells *in vitro*. The observations of the different studies are finally compiled in a summarizing discussion (**Chapter 9**).

## References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001;94:153-156.
2. Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. *Br J Cancer* 1958;12:309-320.
3. Midgley R, Kerr D. Colorectal cancer. *Lancet* 1999;353:391-399.
4. Gatalica Z, Torlakovic E. Pathology of the hereditary colorectal carcinoma. *Fam Cancer* 2008;7:15-26.
5. Lynch HT, Lynch JF, Lynch PM, Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. *Fam Cancer* 2008;7:27-39.
6. Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. *Surg Clin North Am* 2008;88:819-44, vii.
7. Labianca R, Beretta G, Gatta G, de BF, Wils J. Colon cancer. *Crit Rev Oncol Hematol* 2004;51:145-170.

8. Senesse P, Boutron-Ruault MC, Faivre J, Chatelain N, Belghiti C, Meance S. Foods as risk factors for colorectal adenomas: a case-control study in Burgundy (France). *Nutr Cancer* 2002;44:7-15.
9. Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. *J Natl Cancer Inst* 2001;93:525-533.
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759-767.
11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319:525-532.
12. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. *Nature* 1992;359:235-237.
13. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, . Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. *Science* 1991;251:1366-1370.
14. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, . Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991;66:589-600.
15. Aquilina G, Bignami M. Mismatch repair in correction of replication errors and processing of DNA damage. *J Cell Physiol* 2001;187:145-154.
16. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. *Hum Mol Genet* 1996;5 Spec No:1489-1494.
17. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248-5257.
18. de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and colorectal cancer. *Front Biosci* 2007;12:471-491.
19. Reya T, Clevers H. Wnt signalling in stem cells and cancer. *Nature* 2005;434:843-850.
20. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. *Cell* 2000;103:311-320.
21. Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev* 2005;19:2783-2810.
22. ten DP, Hill CS. New insights into TGF-beta-Smad signalling. *Trends Biochem Sci* 2004;29:265-273.
23. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. *Science* 2002;296:1646-1647.
24. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. *Proc Natl Acad Sci U S A* 1995;92:5545-5549.
25. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Jr., Iglehart JD, Marks JR. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. *Cell Growth Differ* 1994;5:1301-1307.
26. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. *J Pathol* 2008;214:283-293.

27. Sier CF, Verspaget HW, Griffioen G, Verheijen JH, Quax PH, Dooijewaard G, De Bruin PA, Lamers CB. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. *Gastroenterology* 1991;101:1522-1528.
28. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, Kristo P, Jarvinen H, Souchelnytskyi S, Sarlomo-Rikala M, Aaltonen LA. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. *Gut* 2002;51:56-59.
29. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. *Cancer Res* 1995;55:5548-5550.
30. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. *Annu Rev Genomics Hum Genet* 2002;3:101-128.
31. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. *Eur J Cancer* 2001;37:224-233.
32. Langenskiold M, Holmdahl L, Falk P, Angenete E, Ivarsson ML. Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. *J Surg Oncol* 2008;97:409-415.
33. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. *Cancer* 1999;85:554-561.
34. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. *J Clin Oncol* 2005;23:2078-2093.
35. Adegboyega PA, Mifflin RC, DiMari JF, Saada JI, Powell DW. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. *Arch Pathol Lab Med* 2002;126:829-836.
36. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC. Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. *Am J Physiol Gastrointest Liver Physiol* 2005;289:G2-G7.
37. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. *Nature* 2004;432:332-337.
38. Van der Flier LG, Clevers H. Stem Cells, Self-Renewal, and Differentiation in the Intestinal Epithelium. *Annu Rev Physiol* 2008.
39. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57-70.
40. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972;26:239-257.
41. Thornberry NA, Lazebnik Y. Caspases: enemies within. *Science* 1998;281:1312-1316.
42. Iqney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer* 2002;2:277-288.
43. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer* 2005;5:231-237.
44. Nagata S. Apoptosis by death factor. *Cell* 1997;88:355-365.

45. Donepudi M, Mac SA, Briand C, Grutter MG. Insights into the regulatory mechanism for caspase-8 activation. *Mol Cell* 2003;11:543-549.
46. Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. *Cell Death Differ* 2007;14:56-65.
47. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. *Cell Death Differ* 1999;6:99-104.
48. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. *Cancer Res* 1995;55:1811-1816.
49. Hashimoto S, Koji T, Kohara N, Kanematsu T, Nakane PK. Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. *Virchows Arch* 1997;431:241-248.
50. Koornstra JJ, De Jong S, Hollema H, De Vries EG, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. *Crit Rev Oncol Hematol* 2003;45:37-53.
51. Evertsson S, Bartik Z, Zhang H, Jansson A, Sun XF. Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma. *Int J Oncol* 1999;15:53-58.
52. Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. *Clin Cancer Res* 1999;5:1793-1804.
53. Takano Y, Saegusa M, Ikenaga M, Mitomi H, Okayasu I. Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. *J Cancer Res Clin Oncol* 1996;122:166-170.
54. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. *Cancer Treat Rev* 2008;34:737-749.
55. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. *Cell Tissue Res* 2000;301:19-31.
56. Barrett KL, Willingham JM, Garvin AJ, Willingham MC. Advances in cytochemical methods for detection of apoptosis. *J Histochem Cytochem* 2001;49:821-832.
57. de Heer P, de Bruin EC, Klein-Kranenburg E, Aalbers RI, Marijnen CA, Putter H, de Bont HJ, Nagelkerke JF, Van Krieken JH, Verspaget HW, van de Velde CJ, Kuppen PJ. Caspase-3 activity predicts local recurrence in rectal cancer. *Clin Cancer Res* 2007;13:5810-5815.
58. de Oca J, Azuara D, Sanchez-Santos R, Navarro M, Capella G, Moreno V, Sola A, Hotter G, Biondo S, Osorio A, Marti-Rague J, Rafecas A. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. *Int J Colorectal Dis* 2007.
59. Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ, van de Velde CJ, Morreau H, Kuppen PJ. Caspase-3 activity as a prognostic factor in colorectal carcinoma. *Lab Invest* 2001;81:681-688.
60. Leonardos L, Butler LM, Hewett PJ, Zalewski PD, Cowled PA. The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. *Cancer Lett* 1999;143:29-35.
61. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resist Updat* 2001;4:303-313.
62. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. *Cancer Res* 1996;56:4006-4012.
63. Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? *Curr Opin Chem Biol* 1999;3:77-83.

64. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell* 2007;11:175-189.
65. Vagefi PA, Longo WE. Colorectal cancer in patients with inflammatory bowel disease. *Clin Colorectal Cancer* 2005;4:313-319.
66. van Hogezaand RA, Eichhorn RF, Choudry A, Veenendaal RA, Lamers CB. Malignancies in inflammatory bowel disease: fact or fiction? *Scand J Gastroenterol Suppl* 2002;48-53.
67. Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN. Mortality in ulcerative colitis. *Gastroenterology* 1982;83:36-43.
68. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;48:526-535.
69. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004;126:451-459.
70. Bernstein CN. Neoplasia in inflammatory bowel disease: surveillance and management strategies. *Curr Gastroenterol Rep* 2006;8:513-518.
71. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;11:314-321.
72. Vleggaar FP, Lutgens MW, Claessen MM. Review article: The relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. *Aliment Pharmacol Ther* 2007;26 Suppl 2:47-52.
73. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. *Gastroenterology* 2003;125:328-336.
74. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. *Surgery* 1998;124:225-231.
75. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. *Carcinogenesis* 1998;19:87-91.
76. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003;348:891-899.
77. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* 2003;348:883-890.
78. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. *Gastroenterology* 2008;134:21-28.
79. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. *Nat Rev Cancer* 2006;6:130-140.
80. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. *Lancet* 2003;362:230.



81. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimpath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR. Primary chemoprevention of familial adenomatous polyposis with sulindac. *N Engl J Med* 2002;346:1054-1059.
82. Giovannucci E. The prevention of colorectal cancer by aspirin use. *Biomed Pharmacother* 1999;53:303-308.
83. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991;325:1593-1596.
84. Murray MD, Brater DC. Effects of NSAIDs on the kidney. *Prog Drug Res* 1997;49:155-171.
85. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. *Gastroenterology* 1993;104:1832-1847.
86. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 1999;340:1888-1899.
87. Ahnen DJ. Colon cancer prevention by NSAIDs: what is the mechanism of action? *Eur J Surg Suppl* 1998;111-114.
88. Clevers H. Colon cancer--understanding how NSAIDs work. *N Engl J Med* 2006;354:761-763.
89. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat Rev Cancer* 2001;1:11-21.
90. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. *J Clin Oncol* 2005;23:2840-2855.
91. de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CA, van den Brule AJ, Van Krieken JH, Rutten HJ, Kuppen PJ, van de Velde CJ. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. *Clin Cancer Res* 2007;13:2955-2960.
92. Tatsu K, Hayashi S, Shimada I, Matsui K. Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis. *Pathol Res Pract* 2005;201:427-433.
93. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology* 1994;107:1183-1188.
94. Ohta T, Takahashi M, Ochiai A. Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. *Cancer Lett* 2005.
95. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. *Carcinogenesis* 1999;20:185-191.
96. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN. Elevated cyclooxygenase-2 levels in Min mouse adenomas. *Gastroenterology* 1996;111:1134-1140.
97. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. *Cancer Res* 2003;63:728-734.
98. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proc Natl Acad Sci U S A* 1999;96:7563-7568.

99. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. *N Engl J Med* 2006;355:885-895.
100. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boissarie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. *N Engl J Med* 2006;355:873-884.
101. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. *Cancer Res* 2006;66:7370-7377.
102. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352:1071-1080.
103. Lu D, Cottam HB, Corr M, Carson DA. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. *Proc Natl Acad Sci U S A* 2005;102:18567-18571.
104. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. *Eur J Cancer* 2000;36:664-674.
105. Svartz M. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa. *Acta Med Scand* 1948;131:465-472.
106. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. *Lancet* 1977;2:892-895.
107. van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. *Gut* 1980;21:632-635.
108. van Bodegraven AA, Mulder CJ. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? *World J Gastroenterol* 2006;12:6115-6123.
109. Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. *Gut* 2000;47:410-414.
110. Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, Soderberg HN, Paumgartner G. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. *Gastroenterology* 1989;97:38-41.
111. Ireland A, Priddle JD, Jewell DP. Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. *Clin Sci (Lond)* 1990;78:105-111.
112. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? *Am J Gastroenterol* 2003;98:2784-2788.
113. Eaden J, Abrams K, Ekobom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000;14:145-153.
114. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. *Gastroenterology* 1989;97:255-259.

115. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. *Dis Colon Rectum* 2001;44:77-85.
116. Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. *Eur J Gastroenterol Hepatol* 1996;8:1179-1183.
117. Pinczowski D, Ekblom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. *Gastroenterology* 1994;107:117-120.
118. Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, Riddell RH, Rutter MD, Ullman TA, Velayos FS, Itzkowitz S. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. *Inflamm Bowel Dis* 2008;14:265-274.
119. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:367-371.
120. Van Staa TP, Card TR, Leufkens HG, Logan RF. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. *Gut* 2005.
121. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. *Am J Gastroenterol* 2005;100:1345-1353.
122. Velayos FS, Loftus EV, Jr., Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. *Gastroenterology* 2006;130:1941-1949.
123. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? *Aliment Pharmacol Ther* 1999;13:1397-1402.
124. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. *Gastroenterology* 1999;116:602-609.
125. Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. *Br J Pharmacol* 1999;128:1361-1369.
126. Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D, Freitag G, Schmiegel W. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. *Endoscopy* 2000;32:245-254.
127. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. *Carcinogenesis* 2003;24:443-451.
128. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. *J Exp Med* 2005;201:1205-1215.
129. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. *Carcinogenesis* 2006;27:2371-2382.

130. Fina D, Franchi L, Caruso R, Peluso I, Naccari GC, Bellinvia S, Testi R, Pallone F, Monteleone G. 5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. *Eur J Cancer* 2006;42:2609-2616
131. Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I, Calabrese E, Naccari GC, Bellinvia S, Testi R, Pallone F. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. *Cell Death Differ* 2006;13:202-211.
132. Fang HM, Mei Q, Xu JM, Ma WJ. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. *World J Gastroenterol* 2007;13:2872-2877.
133. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA Affects Cell Cycle Progression in Colorectal Cells by Reversibly Activating a Replication Checkpoint. *Gastroenterology* 2007;132:221-235.
134. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J. PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. *Carcinogenesis* 2008;29:1407-1414.
135. Schwab M, Reynders V, Steinhilber D, Stein J. Combined treatment of Caco-2 cells with butyrate and mesalazine inhibits cell proliferation and reduces Survivin protein level. *Cancer Lett* 2008;237:98-106.
136. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. *Biochem Pharmacol* 2008;75:668-676.
137. Stolfi C, Fina D, Caruso R, Caprioli F, Fantini MC, Rizzo A, Sarra M, Pallone F, Monteleone G. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. *Carcinogenesis* 2008;29:1258-1266.

